Disposition of patients. Part 2 of the study enrolled a total of 115 patients who previously received imatinib and either dasatinib or nilotinib and 3 patients who previously received all 3 TKIs. *Because of logistical constraints, patients from sites in China, India, Russia, and South Africa were not assessed for molecular response.